Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas

Wang, J.-Y.; Hsueh, P.-R.; Jan, I.-S.; Lee, L.-N.; Liaw, Y.-S.; Yang, P.-C.; Luh, K.-T.
October 2006
Thorax;Oct2006, Vol. 61 Issue 10, p903
Academic Journal
Background: A study was conducted to evaluate the effect of the empirical use of fluoroquinolones on the timing of antituberculous treatment and the outcome of patients with tuberculosis in an endemic area. Methods: All patients with culture confirmed tuberculosis aged ⩾14 years diagnosed between July 2002 and December 2003 were included and their medical records were reviewed. Results: Seventy nine (14.4%) of the 548 tuberculosis patients identified received a Iluoroquinolone (FQ group), 218 received a non-fluoroquinolone antibiotic (AB group), and 251 received no antibiotics before antituberculous treatment. Fifty two (65.8%) experienced clinical improvement after fluoroquinolone use. In the FQ group the median interval from the initial visit to starting antituberculous treatment was longer than in the AB group and in those who received no antibiotics (41 v 16 v7 days), and the prognosis was worse (hazard ratio 6.88 (95% CI 1.84 to 25.72)). More patients in the FQ and AB groups were aged >65 years (53.2% and 61.0% v 31.5%), had underlying disease (53.2% and 46.8% v 34.3%), and were hypoalbuminaemic (67.2% and 64.9% v 35.1%). Of the nine mycobacterial isolates obtained after fluoroquinolone use from nine patients whose initial isolates were susceptible to ofloxacin, one (11.1%) was resistant to ofloxacin (after fluoroquinolone use for 7 days). Independent factors for a poor prognosis included empirical fluoroquinolone use, age >65, underlying disease, hypoalbuminaemia, and lack of early antituberculous treatment. Conclusions: 14.4% of our patients with tuberculosis received a fluoroquinolone before the diagnosis. With a 34 day delay in antituberculous treatment and more frequent coexistence of underlying disease and hypoalbuminaemia, empirical fluoroquinolone treatment was associated with a poor outcome. Mycobacterium tuberculosis isolates could obtain ofloxacin resistance within 1 week.


Related Articles

  • Synthesis and antitubercular activity of new N,N-diaryl-4-(4,5-dichloroimidazole-2-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxamides. Amini, M.; Navidpour, L.; Shafiee, A. // DARU;2008, Vol. 16 Issue 1, p9 

    Background and the propose of the study: Dihydropyridines having carboxamides in 3 and 5 positions show anti-tuberculosis activity. The purpose of the present study was to synthesize new DHPs having possible anti-tuberculosis activity. Methods: 4.5-Dichloroimidazole-2-carboxaldehyde was...

  • Synthesis of some 2,3-disubstituted quinazolinone derivatives as antitubercular and antibacterial activity agents. Subramaniam, Rajasekaran; Rao, Gopalkrishna; Jaiswal, Puneet Kumar // Der Pharmacia Sinica;2014, Vol. 5 Issue 3, p37 

    Currently, one third of the world's population is infected with Mycobacterium tuberculosis and 8.9 to 9.9 million new and relapse cases of tuberculosis are reported every year. The emergence of new cases, the increased incidence of multi-drug resistant strains of M. tuberculosis, and the adverse...

  • capreomycin.  // Royal Society of Medicine: Medicines;2002, p135 

    This article provides information on capreomycin, an antibacterial and antibiotic drug. It is used specifically in the treatment of tuberculosis that proves to be resistant to the first-line drugs, or in cases where those drugs are not tolerated. Administration is by injection. There may be...

  • Drugs that Inhibit Mycolic Acid Biosynthesis in Mycobacterium tuberculosis - An Update. Basso, L. A.; Santos, D. S. // Medicinal Chemistry Reviews - Online;Oct2005, Vol. 2 Issue 5, p393 

    Tuberculosis (TB) remains the leading cause of mortality due to a bacterial pathogen, Mycobacterium tuberculosis, and infects approximately 32 % of the world's human population. It is estimated that 8.2 million new TB cases occurred worldwide in the year 2000, with approximately 1.8 million...

  • Recent Advances in New Structural Classes of Anti-Tuberculosis Agents. Nayyar, Amit; Jain, Rahul // Current Medicinal Chemistry;2005, Vol. 12 Issue 16, p1873 

    Tuberculosis (TB) is one of the most devastating diseases primarily due to several decades of neglect, and presents a global health threat of escalating proportions. TB is the second leading infectious cause of mortality today behind only HIV/AIDS. The impetus for developing new structural...

  • Effective Interventions and Decline of Antituberculosis Drug Resistance in Eastern Taiwan, 2004-2008. Yi-Ting Chen; Jen-Jyh Lee; Chen-Yuan Chiang; Gee-Gow Yang; Yeong-Chu Tsai; Yeong-Sheng Lee; Chih-Bin Lin // PLoS ONE;Feb2012, Vol. 7 Issue 2, p1 

    Background: The Taiwan health authority recently launched several tuberculosis (TB) control interventions, which may have an impact on the epidemic of drug-resistant TB. We conducted a population-based antituberculosis drug resistance surveillance program in Eastern Taiwan to measure the...

  • Development of New Molecular Entities as Potent Antimycobacterial Agents: Synthesis of Substituted Quinazolines. Gangadasu, Hanimi Reddy; Himabindu, V.; Akula, Kalyan Chakravarthy; Shiradkar, Mahendra // Journal of Pharmacy Research;2012, Vol. 5 Issue 5, p2538 

    The re-emergence of tuberculosis infections which are resistant to conventional drug therapy has demonstrated the need for alternative chemotherapy against Mycobacterium tuberculosis. As part of a study to optimize the quinazolines antibacterials against M. tuberculosis, we have prepared several...

  • ASSESSMENT AND ENHANCING ADHERENCE TO TREATMENT REGIMEN IN TUBERCULOSIS OUT PATIENTS. Bhardwaj, Alok; Kumar, Rajeev; Dabas, Vivek; Alam, Niyaz // International Journal of Pharmacy & Pharmaceutical Sciences;Jul2012, Vol. 4 Issue 3, p517 

    Objectives: The objectives of the study were to describe the pattern and monitoring the medication compliance of anti-tubercular used in patients and to assess the knowledge among patients regarding their medications. Methods: During the 7 months prospective study, a suitably designed patient...

  • A study of Non - Compliance by patients of Tuberculosis to DOTS therapy. Shah, Bhavik // New Indian Journal of Surgery;Oct2011, Vol. 2 Issue 4, p235 

    It is mandatory for TB patients to take Anti TB drugs in correct and complete form. Many a time long duration of treatment leads to non-adherence to treatment. Poor adherence to treatment leads to emergence of multidrug- resistant bacilli, so ensuring compliance is of utmost importance to...


Read the Article


Sign out of this library

Other Topics